Iontophoretic R-apomorphine delivery in combination with surfactant pretreatment: In vitro validation studies

International Journal of Pharmaceutics

Volumn 266, Issue 1-2, 2003, Pages 61-68

  Li, Gai Ling ^a   Grossklaus, Arne ^a   Danhof, Meindert ^a   Bouwstra, Joke A ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Iontophoresis; Parkinson's disease; R apomorphine; Surfactant pretreatment

Indexed keywords

APOMORPHINE; LAURETH 3 OXYETHYLENE ETHER; LAURETH 7 OXYETHYLENE ETHER; NONIONIC SURFACTANT; SODIUM SULFOSUCCINATE; SURFACTANT; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DENSITY; DERMATOME; DRUG COMBINATION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG EFFECT; DRUG FORMULATION; DRUG TRANSPORT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IONTOPHORESIS; METABOLISM; METHODOLOGY; PRIORITY JOURNAL; ROOM TEMPERATURE; SKIN; STEREOISOMERISM; STRATUM CORNEUM; TIME; TRANSPORT KINETICS; VALIDATION PROCESS;

EID: 0141922916     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00381-8     Document Type: Article

References (22)

1. Baillie A.J., Florence A.T., Hume L.R., Muirhead G.T., Rogerson A. The preparation and properties of niosomes-nonionic surfactant vesicles. J. Pharm. Pharmacol. 37:1985;863-868.
2. Bhatia K.S., Singh J. Synergistic effect of iontophoresis and a series of fatty acids on LHRH permeability through porcine skin. J. Pharm. Sci. 87:1998;462-469.
3. Burnette R.R., Marrero D. Comparision between the iontophoretic and passive transport of thyrotopin releasing hormone across excised nude mouse skin. J. Pharm. Sci. 75:1986;738-743.
4. Colosimo C., Merello M., Albanese A. Clinical usefulness of apomorphine in movement disorders. Clin. Neuropharmacol. 17:1994;243-259.
5. Frankel J.P., Lees A.J., Kempster P.A., Stern G.M. Subcutaneous apomorphine in the treatment of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry. 53:1990;96-101.
6. Guy R.H., Kalia Y.N., Delgado-Charro M.B., Merino V., Lopez A., Marro D. Iontophoresis: electroreplusion and electroosmosis. J. Control. Rel. 64:2000;129-132.
7. Kalia Y.N., Guy R.H. Interaction between penetration enhancers and iontophoresis: effect on human skin impedance in vivo. J. Control. Rel. 44:1997;33-42.
8. Kleedorfer B., Turjanski N., Ryan R., Lees A.J., Milroy C., Stern G.M. Intranasal apomorphine in Parkinson's disease. Neurology. 41:1991;761-762.
9. Li G.L., Danhof M. Iontophoretic delivery of apomorphine in vitro: physicochemical considerations. Pharm. Res. 18:2001;1509-1513.
10. Li G.L., Danhof M., Frederik P.M., Bouwstra J.A., 2002. Pretreatment with a water-based surfactant formulation affects transdermal iontophoretic delivery of R-apomorphine in vitro. Pharm. Res. (submitted).
11. Miller L.L., Kolaskie C.J., Smith G.A., Rivier J. Transdermal iontophoresis of gonadotropin releasing hormone (LHRH) and two analogues. J. Pharm. Sci. 79:1990;490-493.
12. Mitragotri S. Synergistic effect of enhancers for transdermal drug delivery. Pharm. Res. 17:2000;1354-1359.
13. Montastruc J.L., Rascol O., Senard J.M., Gualano V., Bagheri H., Houin G., Lees A., Rascol A. Sublingual apomorphine in Parkinson's disease: a clinical and pharmacokinetic study. Clin. Neuropharmacol. 14:1991;432-437.
14. Muguet D., Broussolle E., Chazot G. Apomorphine in patients with Parkinson's disease. Biomed Pharmacother. 49:1995;197-209.
15. Nair V., Pillai O., Poduri R., Panchagnula R. Transdermal iontophoresis. Part I. Basic principles and considerations. Methods Find. Exp. Clin. Pharmacol. 21:1999;139-151.
16. Sato J., Denda M., Nakanishi J., Nomura J., Koyama J. Cholesterol sulfate inhibits proteases that are involved in desquamation of stratum corneum. J. Invest. Dermatol. 111:1998;189-193.
17. Singh S., Bi M., Jayaswal S.B., Singh J. Effect of current density on the iontophoretic permeability of benzyl alcohol and surface characteristics of human epidermis. Int. J. Pharm. 166:1998;157-166.
18. van der Geest R., Danhof M., Boddé H.E. Iontophoretic delivery of apomorphine I: in vitro optimisation and validation. Pharm. Res. 14:1997a;1797-1802.
19. van der Geest R., van Laar T., Gubbens-Stibbe J., Boddé H.E., Danhof M. Iontophoretic delivery of apomorphine II: an in vivo study in patients with Parkinson's disease. Pharm. Res. 14:1997b;1804-1810.
20. van der Geest R., van Laar T., Kruger P.P., Gubbens-Stibbe J.M., Boddé h.e., Roos R.A.C., Danhof M. Pharmacokinetics, enantiomer interconversion and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. Clin. Neuropharmacol. 21:1998;159-168.
21. van Laar T., Jansen E.N.H., Neef C., Danhof M., Roos R.A.C. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov. Disord. 10:1995;433-439.
22. van Laar T., van der Geest R., Danhof M., Boddé H.E., Goossens H., Roos R.A.C. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease. Clin. Neuropharmacol. 21:1998;152-158.